Pattern of use of intravitreal drugs with antiangiogenic properties for age-related macular degeneration and other vascular retinopathies (Anti-VEGF drugs)

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study

Non-interventional study

• Scope of the study:
  Drug utilisation
• Data collection methods:
  Secondary data collection
• Non-interventional study design:
  Other
• Non-interventional study design, other:
  Pharmacoepidemiological study

Study drug and medical condition

• Anatomical Therapeutic Chemical (ATC) code:
  100000096721

  bevacizumab

  100000098481

  dexamethasone

  100000098600

  pegaptanib

  100000098601

  ranibizumab

  100000135940

  aflibercept
• Medical condition to be studied:
  Diabetic retinopathy

  Diabetic retinal oedema

  Age-related macular degeneration

Population studied

• Short description of the study population:
  Patients with diabetic retinopathy, retinal oedema or age-related macular degeneration in the Tuscany region of Italy, from 2011 to 2015.
• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Special population of interest:
  Other
• Special population of interest, other:
  Patients with diabetic retinopathy, retinal oedema or age-related macular degeneration
• Estimated number of subjects:
  15000

Study design details

• Main study objective:
  To describe the pattern of use of anti-VEGF drugs for the treatment of age-related macular degeneration and other vascular retinopathies in clinical practice in Tuscany, Italy
• Outcomes:
  Number of injections per year and intra-injections interval, switchingless than 5 injections in the first year
• Data analysis plan:
  Outcomes will be compared across incident users of the drugs. Subgroup analysis will be performed in patients with a sufficient number of contacts with ophthalmic services (interval between consecutive contacts not longer than 3 months) and in patient with at least 3 injections

Documents

Results tables

report_antiVEGF

Study publications

Farmaco-utilizzazione di farmaci per il trattamento della degenerazione macular…